ArticleThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale2025
Carbapenem-Resistant Enterobacteriaceae Bloodstream Infections in Neonates: Clinical Characteristics and Antimicrobial Therapy.
Article in The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Carbapenem-Resistant Enterobacteriaceae Bloodstream Infections in Neonates: Clinical Characteristics and Antimicrobial Therapy.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: To analyze the clinical characteristics, antimicrobial therapies, and outcomes of neonates with carbapenem-resistant Enterobacteriaceae (CRE) bloodstream infections. Methods: This single-center retrospective study included 22 neonates with CRE bloodstream infections at a tertiary children's hospital in China (September 1, 2019-August 31, 2024). Data of clinical characteristics, risk factors, pathogens, carbapenemase testing, antimicrobial therapy, and outcomes were analyzed. Results: All 22 neonates had hospital-acquired late-onset infections (males, 77.3%; preterm infants, 81.8%). Prior to onset, 72.7% of the neonates had a history of broad-spectrum antibiotic exposure. Conclusion: Neonates with immature immunity are more susceptible to CRE bloodstream infections, but clinical cure could be achieved after effective antimicrobial therapy. Carbapenemase testing plays a crucial role in the decision making on treatment of neonatal CRE infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.